Therapeutic Advances in Neurological Disorders
Journal Highlights
- Launched in 2008.
- Gold open access journal – all articles are made freely available online immediately upon publication.
- Rigorous peer review.
- Listed in PubMed Central and indexed in Web of Science, Science Citation Index Expanded (SCIE) and Scopus.
- A leading gold open access in clinical neurology.
- Over 400k full-text article views annually.
Therapeutic Advances in Neurological Disorders (TAND) is a peer-reviewed open access journal which focuses on pioneering efforts and innovative studies across all areas of neurology. Please see the Aims and Scope tab for further information.
This journal is a member of the Committee on Publication Ethics (COPE).
This journal flipped to open access on September 1, 2016.
Diversity, Equity and Inclusion Statement
Therapeutic Advances in Neurological Disorders promotes inclusive, open science that reflects the disciplinary, human, and geographic diversity of the neurology community.
Diversity as a core value embodies inclusiveness, mutual respect, and multiple perspectives.
We welcome editors, editorial board members, peer reviewers and authors from all backgrounds, cultures, ethnicities, nationalities, races, religions, sexes, sexual orientations, gender identities, mental or physical (dis)abilities, ages, career stages, socioeconomic status or any other individual status.
We are committed to continually improving our editorial and review processes whilst playing our part in eradicating bias and inequality in all forms.
Submission information
Submit your manuscript today at http://mc.manuscriptcentral.com/tand.
Please see the Submission Guidelines tab for more information on how to submit your article to the journal.
Open access article processing charge (APC) information
Unsolicited manuscripts submitted to Therapeutic Advances in Neurological Disorders are subject to an Article Processing Charge (APC) of $3,000 USD payable upon acceptance. The article processing charge for Plain Language Summary is $5,000 USD. These articles will be published under a Creative Commons licence and will be made openly available.
The article processing charge (APC) is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Please see further details here.
Contact
Please direct any queries to neuro@sagepub.co.uk.
Therapeutic Advances in Neurological Disorders delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of neurological conditions. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in neurology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area.
The editors welcome original research articles across all areas of neurology.
The journal is dedicated to publishing clinical research. We do not publish preclinical research, including basic laboratory research and animal studies.
Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. The trial registry name and URL, and registration number must be included at the end of the abstract.
The journal adheres to a single-blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees.
| Ralf Gold, MD | Dept of Neurology, Ruhr University Bochum, Bochum, Germany |
| Marinos C Dalakas, MD | Thomas Jefferson University, Philadelphia, PA, USA |
| Olaf Stuve, MD, PhD | University of Texas Southwestern Medical Center, Dallas, TX, USA |
| Georgios Tsivgoulis, MD, PhD, MSc, FESO, FEAN, FAAN | Second Dept of Neurology, National & Kapodistrian University of Athens, Athens, Greece |
| Matthew Walker, MA, MB, Bchir, PhD, FRCP | University College London, London, UK |
| Hemi Malkki, PhD | SAGE Publishing, London, UK |
| Lingling Tian, PhD | SAGE Publishing, Shanghai, China |
| Pramila Gawali | SAGE Publishing, India |
| Albert Ludolph, MD | RKU - Universitäts- und Rehabilitationskliniken, Ulm, Germany |
| Praveen Anand, MD | Imperial College London, London, UK |
| Corrado Angelini, MD, PhD | University of Padova, Padova, Italy |
| Melissa Armstrong, MD, MSc, FAAN | University of Florida, Gaineswille, FL, USA |
| Kailash Bhatia, MD | University College London, London, UK |
| Stéphanie Debette, MD, PhD | Bordeaux University Hospital, Bordeaux, France |
| Hans-Christoph Diener, MD, PhD | University Essen, Essen, Germany |
| Peter Goadsby, MBBS, MD, PhD, DSc, FRACP, FRCP | King's College, London, UK |
| Hans-Peter Hartung, MD, PhD, FRCP | Heinrich-Heine University, Düsseldorf, Germany |
| Ryuji Kaji, MD, PhD | Tokushima University Graduate School of Medicine, Tokushima, Japan |
| Michael Kaplitt, MD, PhD | Weill Medical College of Cornell University, New York, NY, USA |
| Trevor Kilpatrick, MBBS PhD FRACP | University of Melbourne, Melbourne, Australia |
| Giuseppe Lanza, MD, PhD, MSc | University of Catania, Catania, Italy |
| Liping Liu, MD, PhD | Beijing Tiantan Hospital, Capital Medical University, Beijing, China |
| Xavier Montalban, MD, PhD, FAAN, FEAN, FCAHS | Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Spain |
| Noriko Nishikawa, MD, PhD | Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan |
| Ichizo Nishino, MD, PhD | National Center of Neurology and Psychiatry, Tokyo, Japan |
| Jiwon Oh, MD, PhD, FRCPC, FAAN | St. Michael's Hospital, Toronto, Canada |
| Jukka Peltola, MD, PhD | Department of Neurology, Tampere University, Tampere, Finland |
| Michael Platten, MD | German Cancer Research Center, Universität Heidelberg, Heidelberg, Germany |
| Felix Rosenow, MD | Universitätsklinikum Frankfurt, Frankfurt am Main, Germany |
| Graeme Sills, PhD | University of Glasgow, Glasgow, UK |
| Per Soelberg Sørensen, MD, DMSc, FAAN | Copenhagen University Hospital, Copenhagen, Denmark |
| Maria Pia Sormani, PhD | University of Genoa, Genoa, Italy |
| Turgut Tatlisumak, MD, PhD | University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden |
| Klaus V Toyka, MD, FRCP | Universität Würzburg, Würzburg, Germany |
| Eugen Trinka, MD, MSC, FRCP | Neuroscience Institute, Christian-Doppler University Hospital, Paracelsus Medical University, Salzburg, Austria |
| Narayanaswamy Venketasubramanian, MBBS, Mmed, FRCP, FAMS, MSc, DLSHTM, Cert Neurosonology, MHlthSci | Raffles Neuroscience Centre, Raffles Hospital, Singapore |
| Marta Waliszewska-Prosól, MD, PhD | Department of Neurology, Wroclaw Medical University, Wroclaw, Poland |
| Shuang Wang, MD, PhD | Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China Hangzhou, China |
| Patrick Wen, MD | Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA, USA |
| Jo Wilmshurst, MB BS, MRCPaed, FCPaed, MD | Red Cross War Memorial Children's Hospital, University of Cape Town, South Africa |
| Xuejun Yang, MD, PhD | Tianjin Medical University General Hospital, Beijing Tsinghua Changgung Hospital, China |
| Cuantao Zuo, MD, PhD | Fudan University, Shanghai, China |
| Eman Hamid Abdel Dayem, PhD, MD | Ain Shams University, Cairo, Egypt |
| Ravindra Arya, MD, DM, FACNS | Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA |
| Andres Barboza, MD, PhD | Neurology Department, Hospital Central De Mendoza, Mendoza, Argentina |
| Melissa Barker-Haliski | University of Washington, Seattle, WA, USA |
| Mahdi Barzegar, MD | University of Toledo, Toledo, OH, USA |
| Álvaro Beltrán-Corbellini, MD, MSc | Department of Neurology, Hospital Ruber Internacional, Madrid, Spain |
| Rajarshi Chakraborty, DM, DNB | Department of Neurology, King George's Medical University, Lucknow, UP, India |
| Jason J Chang, MD | MedStar Washington Hospital Center, Washington, DC, USA |
| Maria Chondrogiorgi, MD, PhD | Medical School, University of Ioannina, Ioannina, Greece |
| Sara Collorone, MD, PhD | Department of Neuroinflammation, UCL Institute of Neurology, University College London, London, UK |
| Emanuele D'Amico, MD, PhD | University of Foggia, Foggia, Italy |
| Lucio D’Anna, MD, PhD | Department of Brain Sciences, Imperial College London, London, United Kingdom |
| Gloria Dalla Costa, MD, MSc | Department of Nutrition, Harvard University, Boston, USA |
| Urs Fisch, MD, PhD | University Hospital Basel, Basel, Switzerland |
| Yi Chao Foong, MBBS, FRACP | Royal Hobart Hospital, Hobart, Australia |
| Matteo Foschi, MD | Santa Maria delle Croci Hospital, Ravenna, Italy |
| Divyani Garg, MD, DM, FRCP | All India Institute of Medical Sciences, New Delhi, India |
| Vasileios Giannopapas, PT, MSc, PhD | Second Department of Neurology, National and Kapodistrian University of Athens, Greece |
| Nourelhoda Ahmed Ahmed Haridy, MD | Department of Neurology, Assiut University, Assiut, Egypt |
| Khalil S. Husari, MD | Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA |
| Luigi Francesco Iannone, MD | Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy |
| Charuta N Joshi, MBBS, MSCS, FAES, CSCN (EEG) | UT Southwestern Medical Center, Dallas, TX, USA |
| Ching Soong Khoo, MD, FRCP | Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia |
| Sini Laakso, MD PhD | Translational Immunology Research Program, University of Helsinki, Helsinki, Finland |
| Itay Lotan, MD | Department of Neurology, Rabin Medical Center, Petach Tikva, Israel |
| Sushan Luo, MD, PhD | Huashan Hospital, Fudan University, Shanghai, China |
| Omid Mirmosayyeb, MD | University at Buffalo, Buffalo, NY, USA |
| Leonidas D. Panos, MD | Centre Hospitalier Bienne, Bienne, Switzerland |
| Jonathan Pansieri, PhD | University of Oxford, Oxford, UK |
| Mario Prado Jr, MD | University of the Philippines, Quezon, Philippines |
| Andrea Quattrone, MD, PhD | Department of Medical and Surgical Sciences, Institute of Neurology, University Magna Graecia of Catanzaro, Italy |
| Paolo Ragonese, MD, PhD | Department of Biomedicine, Neurosciences and advanced Diagnostics. University of Palermo, Italy |
| Luigi Gianmaria Remore, MD | University of Milan, Milan, Italy |
| Antonella Riva, MD, PhD | University of Genova, IRCCS Istituto Giannina Gaslini, Italy |
| Tamer Roushdy, PhD. MD | Ain Shams University, Cairo, Egypt |
| Philippe Salles, MD | Neuroscience Center, Clínica Universidad de Los Andes, Santiago, Chile |
| Sara Samadzadeh, MD, PHD, MPH, MSc, MSM, FECF | Charité—Universitätsmedizin Berlin, Germany |
| Nahad Sedaghat, MD | Isfahan University of Medical Sciences, Isfahan, Iran |
| Federica Nicoletta Sepe, MD, PhD | IRCCS Mondino, Pavia, Italy |
| Eslam Shosha, MD, FRCPC | McMaster University, Hamilton, Ontario, Canada |
| Charalampos Skarlis, Pharm.D MSc, PhD | Department of Physiology, Medical of Athens National and Kapodistrian University of Athens, Athens, Greece |
| Dilraj Singh Sokhi, FRCPE | Department of Medicine, Aga Khan University, Nairobi, Kenya |
| Gregorio Spagni, MD, PhD | University of Florence, Florence, Italy |
| Marcin Straburzynski, MD, PhD | University of Warmia and Mazury, Poland |
| Tristan T. Sands, MD, PhD | Columbia University Vagelos College of Physicians & Surgeons, New York, NY, USA |
| Aikaterini Theodorou, MD, MSc, PhD | “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece |
| Cristina Valencia-Sanchez, MD, PhD | Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA |
| Claudia Vinciguerra, MD, PhD | University Hospital San Giovanni di Dio e Ruggi D’Aragona, Salerno, Italy |
| Bruno Kusznir Vitturi, MD | Universitätsklinikum Schleswig-Holstein, Kiel and Lübeck, Germany |
| Alessandro Zampogna, MD | Sapienza University of Rome, Rome, Italy |
| Aurora Zanghì, MD | University of Foggia, Foggia, Italy |
| Armin Zarrintan, MD | Mayo Clinic, Rochester, MN, USA |
| Burcu Zeydan, MD | Mayo Clinic, Rochester, MN, USA |
Manuscript Submission Guidelines: Therapeutic Advances in Neurological Disorders
- Open Access
- Article processing charge (APC)
- Article Types
- Editorial policies
4.1 Peer Review Policy
4.2 Authorship
4.3 Acknowledgements
4.4 Funding
4.5 Declaration of conflicting interests
4.6 Research ethics and patient consent
4.7 Clinical Trials
4.8 Reporting guidelines - Publishing policies
5.1 Publication ethics
5.2 Contributor's publishing agreement - Preparing your manuscript
6.1 Word processing formats
6.2 Artwork, figures and other graphics
6.3 Supplementary material
6.4 Reference style
6.5 English language editing services - Submitting your manuscript
7.1 ORCID
7.2 Information required for completing your submission
7.3 Corresponding author contact details
7.4 Permissions - On acceptance and publication
8.1 SAGE Production
8.2 Continuous publication
8.3 Promoting your article - Further information
This Journal is a member of the Committee on Publication Ethics.
This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).
All articles are listed on PubMed.
Please read the guidelines below then visit the journal’s submission site http://mc.manuscriptcentral.com/tand to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.
Only manuscripts of sufficient quality that meet the aims and scope of Therapeutic Advances in Neurological Disorders will be reviewed.
As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.
Therapeutic Advances in Neurological Disorders is an open access, peer-reviewed journal. Each article accepted by peer review is made freely available online immediately upon publication, is published under a Creative Commons license and will be hosted online in perpetuity. Publication costs of the journal are covered by the collection of article processing charges which are paid by the funder, institution or author of each manuscript upon acceptance. There is no charge for submitting a paper to the journal.
For general information on open access at SAGE please visit the Open Access page or view our Open Access FAQs.
2. Article processing charge (APC)
Unsolicited manuscripts submitted to Therapeutic Advances in Neurological Disorders are subject to an article fee of 2,000 USD (+VAT where applicable*) payable upon acceptance. These articles will be published under a Creative Commons Licence and will be made openly available.
Therapeutic Advances in Neurological Disorders considers the following kinds of article for publication:
- Original Articles. The Editors will consider preclinical, interventional and observational studies with clearly stated aims, well-reported methodology (including main outcome measures) and results, and a discussion of the results in the context of the published literature.
- Review Articles. These manuscripts are usually commissioned by the Editors, but the following types of high-quality review will be considered:
(a) General reviews that provide a synthesis of an area that fits within the aims and scope of the journal;
(b) Perspective reviews – review articles that address important new areas of general interest and afford the author the opportunity to present a forward-looking perspective on the topic;
(c) Drug reviews – review articles focusing on the available evidence for the use of a particular drug or combination therapy. - Systematic Reviews – these should answer a specific research question and be reported according to the PRISMA guidelines. They should also include a PRISMA flow chart as a cited figure and a completed PRISMA checklist as a supplementary file (please see section 4.8).
- Meta-analyses – these should answer a specific research question and be reported according to the PRISMA guidelines. They should also include a PRISMA flow chart as a cited figure and a completed PRISMA checklist as a supplementary file (please see section 4.8).
- Case Reports – these structured reports should describe an unusual case and include a full review of the pertinent literature and a section on implications for clinical care.
- Case Series – these descriptive structured reports (which do not involve formal hypotheses or pre-specified methodology or analyses) of a small group of patients should include a full review of the pertinent literature and a section on implications for clinical care.
- Study Protocols – these can be for forthcoming or ongoing research. Information on trial registration (where applicable) and ethics approval should be included in the manuscript.
- Letters to the Editor – these brief opinion pieces should be as concise as possible, usually no more than 1000 words.
The journal considers the results of rigorous, well-designed studies that demonstrate “no effect” or that fail to replicate previous work (“negative data”) as important to the advancement of science. Therapeutic Advances in Neurological Disorders welcomes short reports on null or negative results as long as the papers are based on strong hypothesis testing.
The journal's policy is to obtain at least two independent reviews of each article. Therapeutic Advances in Neurological Disorders operates a conventional single-blind reviewing policy in which the reviewer's name is always concealed from the submitting author. Referees will be encouraged to provide substantive, constructive reviews that provide suggestions for improving the work and distinguish between mandatory and non-mandatory recommendations. All manuscripts accepted for publication are subject to editing for presentation, style and grammar. Any major redrafting is agreed with the author but the Editor's decision on the text is final.
As part of the submission process you will be asked to provide the names of 3 peers who could be called upon to review your manuscript. Recommended reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Please be aware of any conflicts of interest when recommending reviewers. Examples of conflicts of interest include (but are not limited to) the below:
- The reviewer should have no prior knowledge of your submission
- The reviewer should not have recently collaborated with any of the authors
- Reviewer nominees from the same institution as any of the authors are not permitted
You will also be asked to nominate peers who you do not wish to review your manuscript (opposed reviewers).
Please note that the Editors are not obliged to invite/reject any recommended/opposed reviewers to assess your manuscript.
The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor/Board member will have no involvement in the decision-making process.
Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.
The list of authors should include all those who can legitimately claim authorship. This is all those who:
- Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
- Drafted the article or revised it critically for important intellectual content,
- Approved the version to be published,
- Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
4.3.1 Writing assistance
Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance”).
It is not necessary to disclose use of language polishing services.
Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.
Therapeutic Advances in Neurological Disorders requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
4.5 Declaration of conflicting interests
It is the policy of Therapeutic Advances in Neurological Disorders to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.
Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’.
For guidance on conflict of interest statements, please see the ICMJE recommendations.
4.6 Research ethics and patient consent
Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.
For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.
Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants.
All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The journal has adopted the Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals published by the International Association of Veterinary Editors.
Journal Title endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable. The trial registry name and URL, and registration number must be included at the end of the abstract.
The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives
SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.
5.1.1 Plagiarism
Therapeutic Advances in Neurological Disorders and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.
5.1.2 Prior publication
If material has been previously published, it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.
5.2 Contributor's publishing agreement
Before publication SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. Therapeutic Advances in Neurological Disorders publishes manuscripts under Creative Commons licenses. The standard license for the journal is Creative Commons by Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. For more information, you are advised to visit SAGE's OA licenses page.
Alternative license arrangements are available, for example, to meet particular funder mandates, made at the author’s request.
The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.
6.2 Artwork, figures and other graphics
For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines.
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplementary files.
Therapeutic Advances in Neurological Disorders adheres to the SAGE Vancouver reference style. Please review the guidelines on SAGE Vancouver to ensure your manuscript conforms to this reference style.
If you use EndNote or Zotero to manage references, you can download the appropriate output style file to help format your references quickly.
6.5 English language editing services
Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.
Therapeutic Advances in Neurological Disorders is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit http://mc.manuscriptcentral.com/tan to login and submit your article online.
IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created. For further guidance on submitting your manuscript online please visit ScholarOne Online Help.
As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE has become a supporting member of ORCID, the Open Researcher and Contributor ID.
ORCID provides a persistent digital identifier that distinguishes researchers from every other researcher and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities ensuring that their work is recognized.
The collection of ORCID iDs from corresponding authors is now part of the submission process of this journal. If you already have an ORCID iD you will be asked to associate that to your submission during the online submission process. If you do not already have an ORCID iD please follow this link to create one.
7.2 Informtion required for completing your submission
You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).
7.3 Corresponding author contact details
Provide full contact details for the corresponding author including email, mailing address and telephone numbers. Academic affiliations are required for all co-authors. These details should be presented separately to the main text of the article to facilitate anonymous peer review.
Please also ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the SAGE Author Gateway
8. On acceptance and publication
If your paper is accepted for publication after peer review, you will first be asked to complete the contributor’s publishing agreement. Once your manuscript files have been check for SAGE Production, the corresponding author will be asked to pay the article processing charge (APC) via a payment link. Once the APC has been processed, your article will be prepared for publication and can appear online within an average of 30 days. Please note that no production work will occur on your paper until the APC has been received.
Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorising the change.
One of the many benefits of publishing your research in an open access journal is the speed to publication. With no page count constraints, your article will be published online in a fully citable form with a DOI number as soon as it has completed the production process. At this time it will be completely free to view and download for all.
Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice. In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich, share, and measure the impact of their article. Find out how to maximise your article’s impact with Kudos.
Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the Therapeutic Advances in Neurological Disorders editorial office as follows:
For all commercial sales and sponsorship enquiries, including advertising, reprints and supplements, please contact:
Commercial Sales Team, London, UK
Tel: +44 20 7336 1205
Email: reprints@sagepub.co.uk